The long-Term prognostic performance of ki-67 in primary operable breast cancer and evaluation of its optimal cutoff value

Applied Immunohistochemistry and Molecular Morphology

Volumn 24, Issue 3, 2016, Pages 159-166

  Cho, Uiju ^a   Kim, Hee Eun ^a   Oh, Woo Jin ^a   Yeo, Min Kyung ^a   Song, Byung Joo ^b   Lee, Ahwon ^a  

^a The Catholic University of Korea   (India)

^b Chungnam National University   (South Korea)

Author keywords

antigen Ki 67; breast cancer; prognosis; survival analysis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CELL COUNT; CORRELATION COEFFICIENT; EYEBALLED ESTIMATE COUNT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MANUAL CELL COUNT; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR VOLUME; AGED; BREAST NEOPLASMS; METABOLISM; PROGNOSIS; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84962581651     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000164     Document Type: Article

References (27)

1. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-1747.
2. Elston C, Ellis I. Pathological prognostic factors in breast cancer: I. The value of histological grade in breast cancer: experience from a large study with long-Term follow-up. Histopathology. 1991;19:403-410.
3. Stuart-Harris R, Caldas C, Pinder SE, et al. Proliferation markers and survival in early breast cancer: A systematic review and meta-Analysis of 85 studies in 32, 825 patients. Breast. 2008;17: 323-334.
4. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311-322.
5. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-Analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65.
6. Kontzoglou K, Palla V, Karaolanis G, et al. Correlation between Ki67 and breast cancer prognosis. Oncology. 2013;84:219-225.
7. Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11: 174-183.
8. Luporsi E, Andre F, Spyratos F, et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: Analytical and critical review. Breast Cancer Res Treat. 2012;132:895-915.
9. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.
10. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
11. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
12. Keam B, Im S-A, Lee K-H, et al. Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 2011;13:R22.
13. Cheang M, Chia S, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-750.
14. Klintman M, Bendahl PO, Grabau D, et al. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol. 2010;23:251-259.
15. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: A meta-Analysis of published studies involving 12, 155 patients. Br J Cancer. 2007;96:1504-1513.
16. Viale G, Regan M, Mastropasqua M, et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008;100:207-212.
17. Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539-552.
18. Aleskandarany M, Green A, Benhasouna A, et al. Prognostic value of proliferation assay in the luminal, HER2-positive, and triplenegative biologic classes of breast cancer. Breast Cancer Res. 2012;14:R3.
19. Urruticoechea A, Smith I, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212-7220.
20. Neri A, Marrelli D, Pedrazzani C, et al. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer. Eur J Surg Oncol. 2008;34:1299-1303.
21. Li F-Y, Wu S-G, Zhou J, et al. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: A retrospective cohort study. PLoS One. 2014;9:e87264.
22. Dowsett M, Nielsen TO, AHern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103: 1656-1664.
23. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300-313.
24. Bosman FCF, Hruban R, Theise N, et al. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010.
25. Tang LH, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with carcinoma of the endocrine pancreas. 2012. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/2012/PancreasEndo-12protocol-3200.pdf. Accessed Aug 21, 2014.
26. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.
27. Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al. A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. Breast Cancer Res. 2014;16:R35.